Abbott Laboratories (ABT) Notes Payables (2009 - 2021)

Abbott Laboratories (ABT) has 13 years of Notes Payables data on file, last reported at $197.0 million in Q3 2021.

• For the quarter ending Q3 2021, Notes Payables fell 5.29% year-over-year to $197.0 million; the trailing twelve-month figure through Sep 2021 stood at $197.0 million (down 5.29% YoY), and the FY2020 full-year result was $213.0 million, up 5.97% from the prior year.
• Notes Payables slipped to $197.0 million in Q3 2021, from $199.0 million in the prior quarter.
• In the past five years, Notes Payables ranged from a high of $341.0 million in Q2 2018 to a low of $197.0 million in Q3 2021.
• A 5-year average of $213.6 million and a median of $205.0 million in 2020 frame the typical range for Notes Payables.
• Across the five-year window, Notes Payables tumbled 92.46% in 2017 and soared 56.42% in 2018, its largest moves.
• Tracing ABT's Notes Payables over 5 years: stood at $206.0 million in 2017, then decreased by 2.91% to $200.0 million in 2018, then grew by 0.5% to $201.0 million in 2019, then increased by 5.97% to $213.0 million in 2020, then retreated by 7.51% to $197.0 million in 2021.
• Business Quant data shows ABT's Notes Payables at $197.0 million in Q3 2021, $199.0 million in Q2 2021, and $199.0 million in Q1 2021.